rexresearch.com
Catharina Svanborg, et al.
Breast Milk vs Cancer
https://www.naturalnews.com/2018-07-23-the-unique-complex-of-protein-and-fats-found-in-human-breast-milk-kills-over-40-types-of-cancer.html
The unique complex of protein and fats
found in human breast milk KILLS over 40 types of cancer
by: Vicki Batts
Breast milk as a cancer-killer
Professor Catharina Svanborg has been paving the road to
capitalizing on breast milk’s cancer-fighting abilities out of her
lab at Lund University in Sweden. Specifically, the professor has
been working on a way to bind a breast milk protein known as
alpha-lactalbumin to oleic acid, a fatty acid found in olive oil,
nuts and seeds.
The cancer-killing combination she’s dubbed HAMLET (an acronym for
human alpha-lactalbumin made lethal to tumor cells) has shown
great success in laboratory applications, shrinking brain, bladder
and colon tumors with ease. Tests involving animal and human
cancer cell lines have shown that HAMLET is effective against at
least 40 types of cancer.
“Looking down the microscope at the dying tumor cells, we were
quite excited, especially when the experiment was repeated and
showed the same effect twice. We had used non-cancerous cells for
a long time in similar experiments and they had not died,”
Svanborg told The Telegraph, speaking about the amazing way breast
milk kills cancer.
But the funny thing is that Svanborg discovered all of this two
decades ago.
Overcoming skepticism and doubt
Svanborg reportedly went onto patent her confirmed discovery in
1995. She published her research, hoping to take the cancer
industry by storm with her amazing find. But instead of being met
with praise and applause, she was simply met with disbelief.
“There was a certain degree of skepticism. It is about being let
into the cancer community more than anything else,” the professor
contended. As a university professor and immunologist, Svanborg
wasn’t considered part of the cancer or pharmaceutical industries
— and she struggled to have her work taken seriously. As a
specialist in infectious diseases, and a threat to the
profit-driven cancer industry, her research on breast milk and
cancer fell on deaf ears.
But Svanborg was determined and would not be deterred. “One has to
be stubborn when it is a journey into unchartered territory,” she
said. For the last 20 years, Svanborg has continued her research
and continues to turn her skeptics into believers, one by one.
“It is an absolutely thrilling project. If you hang in there, it
opens up new ways of thinking about protein structure, cell
biology and the nature of cancer. People are coming around to the
fact that this is very well supported by in-depth studies,”
Svanborg contended. The team recently developed a way to mass
produce HAMLET, which means it could soon become a widely used
cancer treatment. Her game-changing discovery promises to kill
cancer cells without damaging health cells — a feat that eludes
conventional treatments like chemo.
Though HAMLET still has a ways to go before becoming an approved
form of treatment that’s available to the masses, Svanborg remains
hopeful....
https://www.telegraph.co.uk/health-fitness/body/meet-woman-trying-cure-cancer-breast-milk/
Meet the woman trying to cure cancer
through breast milk
In a picturesque medieval town stands the ivy-covered Lund
University, proudly displaying a historic crest dating back to
1666.
The exterior of this Swedish institution may exude heritage but
inside its thick stone walls, pioneering scientists are crossing
new frontiers in cancer research.
Leading the charge is Professor Catharina Svanborg, who has spent
the past two decades experimenting with human breast milk.
As unbelievable as it sounds, back in the early Nineties, Svanborg
and her postgraduate student Anders Håkansson accidently
discovered that a protein found in breast milk can kill cancer
cells.
They were experimenting with breast milk to try to understand how
it was able to fight off germs. A common scientific practice is to
use human cancer cells in these tests because they behave
similarly to other human cells and live indefinitely in laboratory
dishes.
"There was a certain degree of scepticism. It is about being let
into the cancer community more than anything else"Prof Svanborg
To their surprise, the pair realised that the cancer cells were
inexplicably disappearing and on closer inspection Svanborg
realised the breast milk was causing them to "commit suicide".
"Looking down the microscope at the dying tumor cells, we were
quite excited, especially when the experiment was repeated and
showed the same effect twice. We had used non cancerous cells for
a long time in similar experiments and they had not died," she
explains.
Further in vitro experiments confirmed that when human milk
protein (called alpha-lactalbumin) binds to a fatty acid it
creates a unique tumour-killing protein-lipid complex that has the
ability to destroy cancer cells. It rapidly shrinks the most
aggressive type of invasive brain tumour as well as bladder cancer
and colon cancer tumours.
Svanborg named this Hamlet (Human alpha-lactalbumin made lethal to
tumour cells) and patented the discovery. She then set about
informing the scientific world and published her first research
paper in one of the most-cited multidisciplinary scientific
journals, the Proceedings of the National Academy of Science, in
1995.
But instead of being met with worldwide acclaim, Svanborg and her
associates were met with disbelief.
As an immunologist working in a university, Svanborg was not part
of the cancer research and pharmaceutical development community,
and initially struggled to have her research taken seriously.
Her expertise in infectious disease, rather than cancer research,
meant that Svanborg had less clout - particularly as she was
challenging the current dogma.
Back in 1999, David Salomon - a cancer researcher at the National
Cancer Institute in America - told Discovery magazine that if
Svanborg's research had come from a well known laboratory,
journalists would be calling "six days to Sunday. You’d have
scientists eager to collaborate. But it’s coming from a small lab
in a foreign country. It’s like General Motors versus a garage
operation.”
It's something Svanborg is all too aware of. "There was a certain
degree of scepticism" she says, choosing her words carefully. "It
is about being let into the cancer community more than anything
else.
"A common response I’d get would be 'we don't get it, but we can't
fault the research'," says Svanborg.
Undeterred, she doggedly set off to "take the tiger by the tail"
and prove her discovery was legitimate: "One has to be stubborn
when it is a journey into unchartered territory".
So, for the past 20 years, she has been doing just that - breaking
new ground and slowly winning over the sceptics by building up a
wealth of conclusive scientific data. Her small team of around a
dozen scientists have been testing Hamlet on animals and humans,
showing time and again that it can kill over 40 cancers but leaves
healthy cells unharmed.
Tests on mice revealed that Hamlet limited the development of
brain tumours and bladder cancer. It also prevented the
development of colon cancer in baby mice, when given in their
drinking water, suggesting that it might also be developed to
prevent tumour development in genetically susceptible individuals.
In one human test, nine bladder cancer patients were administered
five daily doses of Hamlet via a catheter in the week preceding
surgery to remove their tumour. Eight out of the nine started
passing tumours cells in their urine just two hours after being
given it, and their tumour reduced in size or character. Adjacent
healthy tissue showed no sign of toxicity.
These types of breakthroughs have kept Svanborg determined to get
her treatment onto the market. She has used the years judiciously
to amass a convincing body of data, including scores of articles
in prestigious science journals such as The International Journal
of Cancer, Oncogene, Experimental Cell Research and Molecular
Microbiology.
"This is a game-changing discovery for potential cancer treatments
for the future"Prof Svanborg
She remains excited as ever about the research: "It is an
absolutely thrilling project. If you hang in there, it opens up
new ways of thinking about protein structure, cell biology and the
nature of cancer. People are coming around to the fact that this
is very well supported by in depth studies."
Indeed other researchers, such as assistant professor Dagmar
Zweytick at the University of Graz in Austria, are now
experimenting with similar techniques using different breast milk
molecules to treat cancer cells in the lab. However their research
is in its infancy with only three publications to date.
With the cancer research community starting to thaw, Svanborg was
in a better position than ever to reveal her latest findings at
the Medela breastfeeding and lactation symposium in Florence,
Italy last week.
Her team has finally discovered how to mass produce a synthetic
form of Hamlet, meaning it is now ready to be developed into a new
cancer treatment drug.
“Who would have thought that breast milk had the potential to kill
cancer cells?” said Dr. Leon Mitoulas, scientific director of the
symposium.
“We are truly on the cusp of a golden age for research in human
milk. It is an infinitely complex fluid, and intensive,
multidisciplinary studies, utilising cutting-edge techniques, have
only been employed in this field the past decade."
Talking from her hotel room in Florence, an elated Svanborg
explains why this innovation is so important.
"Hamlet is ready to become a new drug. We have all the things
ready but we are now proceeding with all the necessary steps,
tests and clinical trials all working towards the goals to create
a new cancer therapy."
These large scale clinical trials will be tested on colon, bladder
and cervical cancer - as well as other forms that have been
historically difficult to cure.
Although there are currently many effective cancer treatments
available, what makes Hamlet unique is its ability to target
specific tumours, with apparently little or no side effects.
Unlike chemotherapy and radiotherapy - which destroy some healthy
cells causing side effects such as nerve damage, loss of hair and
nausea - it is seemingly not toxic to healthy cells.
"This is a game-changing discovery for potential cancer treatments
for the future. To have been leading this project is something
that I am very proud of and I am entirely grateful to all my team
members, who have been working tirelessly, to get where we are
today – in a position of being ready to create a new drug," said
Svanborg.
But the journey is far from over. Hamlet still needs investment
from "big pharma" to become available to the public and Svanborg
won't be drawn on how many years this could take.
“We are not yet able to say when it will be fully tested,
approved, and produced as a cancer therapy drug, but we are
working very hard towards the goal that Hamlet will be available
for patients who need alternative therapies."
And leading research institutions still remain cautious. Dr
Justine Alford, Cancer Research UK’s senior science information
officer, said: “This research doesn’t provide any evidence that
breast milk has any cancer-fighting properties.
"We’re years away from knowing whether the drug is better than
existing treatments and we’ll need to wait for results from larger
clinical trials to find out"Dr Justine Alford, Cancer Research UK
“Research has shown that a man-made version of a molecule found in
breast milk has some positive effects treating mice with cancer,
and early clinical trial results show that the drug is safe for
people to take.
“But we’re years away from knowing whether the drug is better than
existing treatments and we’ll need to wait for results from larger
clinical trials to find this out.
“Developing a new cancer treatment can take a long time, because
all new drugs have to be rigorously tested to make sure they are
safe and stand a good chance of working before they are tested in
people.”
Committed as ever and convinced of the importance of her
discovery, Svanborg is now putting everything in place to hand the
Hamlet baton onto a drug development company.
Like the mother of an extraordinary child - albeit an accidental
one - she is now preparing for her baby to leave the nest.
But despite all her emotional and professional investment in the
project if Hamlet does make it onto the market Svanborg
refuses to profit from it financially.
She says, "The team have all agreed if we ever make money it will
go into a research foundation to channel it back into society."
http://discovermagazine.com/1999/jun/featcancer
Got Cancer Killers?
Breast-feeding protects babies from cancer, but no one knows
quite how. So when biologists in Catharina Svanborg's lab saw
mothers' milk kill cancer cells, they knew they were onto
something big.
By Peter Radetsky, Thomas Wester
When Catharina Svanborg and her research associates began mixing
mothers' milk and cancer cells together seven years ago, she
wasn't looking for a cure for cancer; she was after a way to fight
germs. Nevertheless, the physician and immunologist at Lund
University in Sweden has discovered that a previously
taken-for-granted component of ordinary human breast milk compels
cancer cells -- every type of cancer cell tested -- to die. Now
Svanborg must prove her discovery, demonstrating to wary
scientists that her surprising find is for real. So far, it hasn't
been easy.
“It’s an extremely important observation, interesting and
provocative,” says breast cancer researcher David Salomon of the
National Cancer Institute. “But it’s novel, and novelty always
runs the risk of challenging the current dogma. A lot of times you
run up against a brick wall of people who have tunnel vision.”
It doesn’t help that Svanborg’s lab is not a large, high-profile
cancer research facility. In fact, it’s not a cancer lab at all;
her specialty is an entirely different field, infectious disease.
Says Salomon: “If this work had come from a well-known lab at the
NCI, you’d have reporters calling six days to Sunday. You’d have
scientists eager to collaborate. But it’s coming from a small lab
in a foreign country. It’s like General Motors versus a garage
operation.”
If so, this is the kind of garage you’d take your Porsche to.
Tall, poised, and professional to the core, Svanborg leads a team
of dedicated young researchers who have worked overtime to make
their discovery matter. With the first phase of research finally
finished, the group has decided to launch a fusillade of papers to
scientific journals. Soon skeptics may have a tough time denying
that they are onto something big.
Lund is dark and bleak in winter. A medieval town of 95,000 people
(almost half are students), it nestles into Sweden’s southern tip.
At its heart stands a twelfth-century cathedral with Romanesque
towers that disappear into the gloomy low mist. As an occasional
vehicle slowly skirts the town’s commons, bundled bicyclists glide
by silently. People hunch forward against the cold. Across the
way, university halls from the seventeenth century proclaim in
stone Lund’s role as Scandinavia’s historical center of learning.
So it is a surprise, away from the town center, to come suddenly
upon modern brick and concrete buildings: the university hospital,
the library, science classrooms, laboratories. It was here nearly
seven years ago that her student Anders Håkansson rushed into
Svanborg’s office with perplexing news. He had been experimenting
with human cancer cells, microbes, and mothers’ milk. (Like lab
mice, cancer cells make popular experimental models because they
come in standardized lab strains. In many important respects they
behave just like other human cells, and they live indefinitely in
lab dishes.) The idea was to pinpoint how the milk, a terrific
germ-fighter, blocks bacteria from infecting other cells. But the
cancer cells in this experiment were acting up. “Their volume was
decreasing,” Håkansson recalls. “Their nuclei were shrinking.
Something was wrong.”
When Svanborg sat down at the microscope, she diagnosed the
problem immediately. “The cancer cells,” she announced in her
calm, deliberate manner, “are committing suicide.”
Cells commit suicide all the time, a phenomenon called apoptosis,
in which the body rids itself of old or unnecessary cells (see
“Apoptosis,” on page 73). They simply fall apart and are recycled.
For cancer cells, however, suicide is rare indeed. Their defining
characteristic is uncontrolled reproduction. Yet somehow, the
breast milk induced these cancer cells to take their own lives.
The circumstance opened up an enormous vista of mysteries—which
pleased Svanborg to no end. “Discovery is at the heart of science.
If you ask me for specific goals, I wouldn’t be able to name them.
The process is fascinating enough.” Svanborg was eager to dive
into finding out what in mothers’ milk was killing the cancer
cells.
“And I always hope that new information will be practical and
useful for people who need it,” she adds, the physician rising to
the fore. Discerning the basic mechanism wasn’t enough—Svanborg
wanted to find out if the cells might be induced to commit suicide
on demand: Could the discovery be developed into a cancer cure?
Attempting to do so would require manpower, and fewer than 20
people worked in Svanborg’s lab. Most were already involved in
their own projects targeting infectious diseases. “If this were a
pharmaceutical company, you could say, ‘Take a bunch of people and
move them to this,’” Svanborg says. “But this is a university.
These are students. If they already have thesis projects going,
you can’t change their focus just like that.”
“You have freedom here,” says a graduate student. “Although we’re
still in training, we are working as scientists. Catharina is very
good at giving feedback, but we get to decide what experiments to
do and how to do them.”
Which is also the way their professor likes it: “I want to
facilitate creative environments. I like encouraging people to
contribute based on who they are and what they think. After all,
this cancer find is pure serendipity. And serendipity arises when
people are in a situation that fosters creativity. Nobody can
define how it happens, but there’s a lot of happiness involved.”
So when Svanborg decided to go after the cancer, she couldn’t just
pull her colleagues from their projects to help her. The
undertaking would largely fall to her and Håkansson alone.
Patents
US2015216945
PROPHYLACTIC AND NUTRACEUTICAL THERAPY
A biologically active complex comprising a polypeptide having the
sequence of a naturally occurring protein or a variant thereof,
wherein said polypeptide is at least partially unfolded as
compared to the said naturally occurring protein for example as a
result of a modification of at least one cysteine residue; or a
peptide of up to 50 amino acids; and a fatty acid or lipid or a
salt thereof, for use in prophylactic treatment of cancers, in
particular of the gastrointestinal tract. Compositions that may
comprise the complex and have use as nutraceuticals are obtainable
from milk or milk fractions and form a further aspect of the
invention. Methods of treatment in particular for the prevention
of cancer form a further aspect of the invention.A biologically
active complex comprising a polypeptide having the sequence of a
naturally occurring protein or a variant thereof, wherein said
polypeptide is at least partially unfolded as compared to the said
naturally occurring protein for example as a result of a
modification of at least one cysteine residue; or a peptide of up
to 50 amino acids; and a fatty acid or lipid or a salt thereof,
for use in prophylactic treatment of cancers, in particular of the
gastrointestinal tract. Compositions that may comprise the complex
and have use as nutraceuticals are obtainable from milk or milk
fractions and form a further aspect of the invention. Methods of
treatment in particular for the prevention of cancer form a
further aspect of the invention.
NOVEL THERAPY
US2018125939
A method for treating cystitis, in particular acute cystitis,
comprising administering to a patient in need thereof, an
effective amount of a reagent selected from the group consisting
of IL-1β inhibitors and MMP inhibitors, or proteins selected from
ASC or NLRP-3. Diagnostic methods are also described and claimed.
NOVEL THERAPY
US2018112215
A method for treating cystitis, in particular acute cystitis,
comprising administering to a patient in need thereof, an
effective amount of a reagent selected from the group consisting
of IL-1β inhibitors and MMP inhibitors, or proteins selected from
ASC or NLRP-3. Diagnostic methods are also described and claimed.
THERAPEUTICALLY ACTIVE COMPLEXES
WO2018116165
A biologically active complex comprising a peptide of up to 50
amino acids in length which comprises an alpha-helical domain of a
protein which has membrane perturbing activity or a variant
thereof which lacks cysteine residues, and oleic acid or a salt
thereof, provided the protein is other than alpha-lactalbumin.
Complexes of this type are useful in therapy, in particular cancer
therapy.
INHIBITOR OF RNA POLYMERASE II
WO2018073725
An inhibitor of RNA polymerase II is described, wherein said
inhibitor is selected a moiety which targets a protein selected
from cyclin kinase 12 (CDK12) or its recruiting protein PAF1C.
Particular examples of such inhibitors are polypeptides expressed
by a gene selected from IldD, IldR, nlpD or rfaH of a bacterial
species, such as a commensal bacteria or asymptomatic carrier, or
a variant of said protein. Inhibitors may be based upon bacterial
Sigma S or NplD proteins. These inhibitors are useful in
therapies, to suppress protein expression. Thus they may be used
as immunosuppressants, anti-inflammatory or anti- infection
agents.
NOVEL THERAPY
WO2018069886
A therapeutic agent comprising a bacteria which expresses an
inhibitor of MYC activity or a extract or product obtainable
therefrom, for use in for use in the prevention or treatment o
disease wherein MYC levels are elevated, such as cancer.
Inhibitors of MYC activity comprising a factor obtainable from
bacteria are novel and form a further aspect of the invention.
BIOLOGICALLY ACTIVE COMPLEX AND ITS
PREPARATION
US9085643 // US9487561
Biologically active complex and its preparation A biologically
active complex comprising either a polypeptide having the sequence
of a variant of a naturally occurring protein, wherein said
polypeptide is at least partially unfolded as compared to the said
naturally occurring protein; or a peptide of up to 50 amino acids,
for instance a fragment of the naturally occurring protein or a
variant thereof; and a pharmaceutically acceptable salt of a fatty
acid or lipid. The complexes of the invention demonstrate a novel
mode of action, that gives rise to opportunities for the
development of further active agents and screening methods.
NOVEL THERAPY
WO2018007920
An antagonist of Neurokinin-1 receptor (NKIR), or its ligand
Substance P (SP), for use in the treatment of bacterial
infections, in particular acute cystitis, or for the management of
pain related to the bacterial infection. Compositions for use in
this manner form a further aspect of the invention, together with
methods of treatment.
COMPLEX AND PRODUCTION PROCESS
US8796218
A method for preparing a biologically active complex, said method
comprising a recombinant protein having the sequence of
a-lactalbumin, such as human a- lactalbumin or a fragment thereof
but which lacks intra-molecular disulfide bonds, and oleic acid,
and process for preparing this are described and claimed. The
recombinant protein suitably has cysteines found in the native
protein changed to other amino acids, such as alanine.
Improvements in recombinant expression, process rationalisation
and yields of biologically active complexes, as well as the
complexes obtained are also described and claimed.
LACTALBUMIN PRODUCTION PROCESS
EP1867658
A method for producing an oligomeric form of ±-lactalbumin which
is in the molten globule-like state is described. The method
suitably comprises exposing a source of ±-lactalbumin in which the
±-lactalbumin is preferably in the molten globule-like state, to
an ion exchange medium which has been pre-treated with casein or
an active component thereof, such as oleic acid, and recovering
±-lactalbumin in an oligomeric form therefrom. Pre-treatment of
the ion exchange medium, particularly with casein derived from
human milk, has been found to significantly improve yields of the
oligomeric form of ±-lactalbumin and means that it can readily be
isolated from readily available sources such as bovine
±-lactalbumin. This form of ±-lactalbumin is useful
therapeutically, in particular as an antibacterial agent and also
as an anti-cancer therapeutic.
Therapeutic Combination
US2009036368
A combination of component (i) which is HAMLET or a biologically
active modification thereof, or a biologically active fragment of
either of these, and component (ii) which is a histone deacetylase
(HDAC) inhibitor. This combination shows synergistic effects in
the treatment of for example proliferative diseases such as those
which produce tumours.
Active complex of alpha-lactalbumin
(HAMLET) and cofactor
US7713533
The use of a biologically active complex of alpha-lactalbumin,
selected from HAMLET (human alpha-lactalbumin made lethal to
tumour cells) or a biologically active modification thereof, or a
biologically active fragment of either of these, in the
preparation of a medicament for use in the treatment of papilloma,
such as cutaneous papillomas.
Antibacterial composition
US5968901
The present invention relates to a use of casein derived from
milks, preferably human milk, and porcine milk, for the
preparation of a substrate for the prophylactic and/or therapeutic
treatment of infections of the respiratory tract caused by S.
pneumoniae and/or H. influenzae, as well as the diagnostic use of
such compositions for diagnosing infections caused by said
bacteria.
Protein complex from ion-exchange
chromatography of casein for treatment of bacterial infections
US6599874
Antibacterial protein complexes designated as Anti-adhesive
Lactalbumin Like Protein (ALLP) are obtained by ion-exchange
chromatography of casein and alpha-lactalbumin. Casein isolated
from human milk by acid precipitation is subjected to ion-exchange
chromatography using an NaCl gradient to obtain six fractions.
Fraction six contains the antibacterial protein complex and is
recovered. Ion-exchange chromatography of human or bovine
alpha-lactalbumin using an NaCl gradient resulted in a fraction
that was retained and eluted that contained an antibacterial
multimeric protein complex. The protein complexes inhibit
attachment of S. pneumoniae and H. influenzae to human respiratory
tract epithelial cells when tested in vitro, and the protein
complexes can be used to treat a bacterial infection in the
respiratory tract. The protein complexes are administered in a
pharmaceutical composition or in a food or feed-stuff.
Lactalbumin for Inhibiting Angiogenesis
US2008039381
The use of a biologically active complex of alpha-lactalbumin,
selected from HAMLET (human alpha-lactalbumin made lethal to
tumour cells) or a biologically active modification thereof, or a
biologically active fragment of either of these, in the
preparation of a medicament for use in the treatments of
proliferative disease and in particular of mucosal cancers such as
bladder cancer or malignant melanoma, as well as tumours of
internal organs such as glioblastoma, as well as in the inhibition
of angiogenesis.
Use of Hamlet (Human Alpha-Lactalbumin Made
Lethal to Tumour Cells) for Treating Viral Infections
US2007232550
The use of a biologically active complex of alpha-lactalbumin,
selected from HAMLET (human alpha-lactalbumin made lethal to
tumour cells) or a biologically active modification thereof, or a
biologically active fragment of either of these, in the
preparation of a medicament for use in the treatment of viral
infections.
Therapeutic agents
US6808930
An agent comprising a protein complex comprising an oligomeric
form of alpha-lactalbumin (MAL) and a further reagent which is
combined with MAL such that it is carried into the nucleoplasm of
cells which are susceptible to MAL. Agents of the type, where the
further reagent is a therapeutic or labelling reagent, can be used
in diagnosis and therapy in particular of cancer.
Lactalbumin production process
US7053185
A method for producing an oligomeric form of alpha-lactalbumin
which is in the molten globule-like state is described. The method
suitably comprises exposing
a source of alpha-lactalbumin in which the alpha-lactalbumin is
preferably in the molten globule-like state, to an ion exchange
medium which has been pre-
treated with casein or an active component thereof, such as oleic
acid, and recovering alpha-lactalbumin in an oligomeric form
therefrom. Pre-treatment of
the ion exchange medium, particularly with casein derived from
human milk, has been found to significantly improve yields of the
oligomeric form of alpha-lactalbumin and means that it can be
readily isolated from readily available sources such as bovine
alpha-lactalbumin. This form of alpha-lactalbumin is useful
therapeutically, in particular as an antibacterial agent and also
as an anti-cancer therapeutic.
Novel therapies and methods of screening
for therapeutic compounds
US2006233807
A method for killing cells, said method comprising introducing
into the nucleus of the cell, a moiety (other than HAMLET) which
inhibits histone activity. This
method will be useful for example in the treatment of cancer for
antibacterial activity. Histones can be used as a basis of
screening methods to select therapeutic compounds, and these are
also described and claimed.
Biologically active complex
US2005085416
A biologically active complex comprising alpha-lactalbumin or a
variant of alpha-lactalbumin which is in the apo folding state, or
a fragment of either of any of these, and a cofar which stabilizes
the complex in a biologically active form, provided that any
fragment of alpha-lactalbumin or a variant thereof comprises a
region corresponding to the region of alpha-lactalbumin which
forms the interface between the alpha and beta domains, and
further provided that when the complex comprises native
alpha-lactalbumin, the cofactor is other than C18:1:9 cis fatty
acid. These complexes have therapeutic applications for example in
the treatment of cancer and as antibacterial agents.
Glycosphingalipids for inhibiting bacterial
adherence
US4464360
Pharmaceutical preparations containing globotetraosylceramide,
globotriaozylceramide or globotetraos, and the use of said
preparations or compounds for treatment, prophylaxis or diagnosis
of bacterial infections in the urinary tract. The compounds have
the ability to inhibit the adherence of bacteria to human urinary
tract epithelial cells.
A CASEIN FRACTION FOR THERAPEUTIC,
PROFYLACTIC AND/OR DIAGNOSTIC USE IN INFECTIONS OF THE
RESPIRATORY TRACT
WO9106308
The present invention relates to a use of casein derived from
milks, preferably human milk, and porcine milk, for the
preparation of a substrate for the prophylactic and/or therapeutic
treatment of infections of the respiratory tract caused by S.
pneumoniae and/or H. influenzae, as well as the diagnostic use of
such compositions for diagnosing infections caused by said
bacteria.